Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02111018
Recruitment Status : Unknown
Verified June 2015 by CytoSorbents, Inc. Recruitment status was: Recruiting
First Posted : April 10, 2014
Last Update Posted : June 23, 2015
San Antonio Military Medical Center (SAMMC), US Army Institute of Surgical Research-Burn Center
Prospective, randomized non-blinded, controlled study to assess the feasibility of the CytoSorb as an adjunct to the standard of care in patients with rhabdomyolysis requiring renal replacement therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subject is age 18-80
Subjects present with rhabdomyolysis
Subject requires renal replacement therapy and has undergone adequate volume resuscitation
Subject is willing to comply with specified follow up requirements
Subject or their legal guardian either declines or cannot give informed consent
Subject is pregnant
Subject has been previously enrolled in this clinical study
Comorbid condition that may limit survival to ≤14 days
Comorbid condition that could confound study results
Subjects who are receiving immunosuppressive therapy